Mark T. Bertolini, serving as both Chief Executive Officer and Director of Oscar Health, Inc. (NASDAQ:OSCR), executed a substantial divestment of company equity. Across two trading days on June 25 and June 26, 2026, Bertolini sold a cumulative total of 1,206,310 shares of Oscar Health's Class A Common Stock. The aggregate value of these transactions reached approximately $34,912,078. The execution prices for the shares varied between $28.06 and $30.17 per share. Notably, these sale prices occurred in close proximity to the stock's 52-week high of $30.38. This pricing context aligns with a broader market trend for Oscar Health, where shares have appreciated by 105% over the preceding six-month period.
The structural mechanics behind this divestment are tied to corporate compensation protocols. The transactions were specifically undertaken to satisfy tax withholding obligations. These obligations stem from the deferred settlement of performance stock units and time-based restricted stock units that vested on April 3, 2026. To facilitate the orderly execution of these sales, the company utilized a Rule 10b5-1 trading plan. This pre-arranged trading framework was initially established on November 10, 2025, and was subsequently amended and restated on March 24, 2026.
Following the completion of these sales, Bertolini's direct ownership position in Oscar Health Class A Common Stock stands at 8,990,566 shares. This remaining equity stake includes shares that are slated for issuance in connection with the vesting of one or more restricted stock units. The health insurance company currently carries a market valuation of $8.8 billion. Financial projections for the insurer anticipate a return to profitability within the current year. Analyst forecasts for earnings per share stand at $1.23.
Broader market developments are occurring concurrently with these executive transactions. Oscar Health has experienced a series of notable shifts in analyst sentiment and corporate structure. Barclays recently upgraded the company's stock rating from Equalweight to Overweight. This upgrade cites valuation potential and includes a revised price target of $35. The analyst firm's decision reflects expectations of a multi-year re-rating and margin recovery for the insurer.
Wells Fargo also adjusted its stance on Oscar Health, moving the rating from Underweight to Equal Weight. This institution set a new price target of $20. The upgrade highlights confidence in the exchange market trajectory for 2026. Separately, Raymond James reiterated an Outperform rating for the stock. This firm maintained a $30 price target following a federal judge's decision regarding marketplace regulations.
Corporate leadership adjustments are also underway. Oscar Health announced changes to the role of Mario Schlosser. Schlosser is transitioning to the position of Co-Founder and Advisor to the CEO. He will continue to support artificial intelligence and digital health initiatives within the organization.
Market activity indicators suggest heightened investor interest in the stock. Trading volume in the options market for Oscar Health surged, with 52,384 contracts traded. Recent price data shows the stock at 29.45, down 0.34 or 1.14% at close. After hours trading indicated a further decline to 28.65, down 0.80 or 2.72%.
The combination of executive stock sales, analyst upgrades, and leadership restructuring underscores a dynamic environment for Oscar Health. These factors collectively position the company for potential future growth as it navigates regulatory and market conditions.